Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02734862 · ClinicalTrials.gov registry record · Phase 2
CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension
A Phase 2 study of Candidemia and Mycoses, sponsored by Cidara Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 207
- Enrollment target
- 20
- Study locations
NCT02734862: Completed Phase 2 study of Candidemia and Mycoses, sponsored by Cidara Therapeutics.
NCT02734862 is a Phase 2 study of Candidemia and Mycoses that has completed, run by Cidara Therapeutics. The registered enrollment target is 207 participants, below the 388-participant average among 8 other Candidemia trials with a reported enrollment target (47% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02734862, a Phase 2 study of Candidemia and Mycoses, has completed, sponsored by Cidara Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 207 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine if intravenous CD101 is safe and effective in the treatment of candidemia and/or invasive candidiasis when compared to caspofungin (followed by oral fluconazole).
Primary Outcome
Number of Subjects with Incidence of Treatment Emergent Adverse Events based on clinical chemistry, hematology and urine analysis laboratory test, vital sign, physical exams and ECG abnormalities.
Conditions Studied
Interventions
- DRUG Fluconazole
- DRUG Caspofungin
- DRUG oral placebo
- DRUG CD101
- DRUG intravenous placebo
Study Locations (20)
Other
- Jules Bordet Institute - Brussels
- CHU Brugman - Brussels
- Erasme Hospital - Brussels
- UCL Saint-LUC - Brussels
Michigan
- Harper University Hospital - Detroit
- Henry Ford Health System - Detroit
- William Beaumont Hospital - Royal Oak
Alabama
- University of Alabama at Birmingham - Birmingham
California
- University of California - Davis - Davis
Florida
- University of Miami Miller School of Medicine - Miami
Georgia
- Augusta University - Augusta
Massachusetts
- Brigham and Women's Hospital - Boston
Mississippi
- University of Mississippi Medical Center - Jackson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 207 participants |
| Start Date | 2016-07-26 |
| Est. Completion | 2019-07 |
| Phase | Phase 2 |
What the finished NCT02734862 record still lists
NCT02734862 is an interventional study that assigns participants to a tested intervention. The registered 207 participants enrollment target is mid-sized for trials with a published cap, below the 388-participant average among 8 other Candidemia trials with a reported enrollment target (47% lower).
The record links to 5 conditions, with Candidemia appearing as the primary indexed condition, and to 5 interventions - of which Fluconazole is the first listed.
NCT02734862 names 20 study sites across 15 states, led by Other, Michigan, Alabama.
Frequently Asked Questions
What is clinical trial NCT02734862 about?
NCT02734862 is a clinical study titled "CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension". The purpose of this study is to determine if intravenous CD101 is safe and effective in the treatment of candidemia and/or invasive candidiasis when compared to caspofungin (followed by oral fluconazole).
What is the current status of trial NCT02734862?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 207 participants. The study started on 2016-07-26. Estimated completion is 2019-07.
What conditions does trial NCT02734862 study?
This clinical trial studies the following conditions: Candidemia, Mycoses, Fungal Infection, Invasive Candidiasis, Fungemia.
What interventions are being tested in trial NCT02734862?
The interventions under investigation include: Fluconazole (DRUG), Caspofungin (DRUG), oral placebo (DRUG), CD101 (DRUG), intravenous placebo (DRUG).
Who is sponsoring clinical trial NCT02734862?
This trial is sponsored by Cidara Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02734862 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Candidemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02734862's enrollment target sits among peer trials
207 6th of 8 higher than 3 of 8 other Candidemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Candidemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia
RECRUITING · Phase 2
-
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
RECRUITING · Phase 3
-
Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation
ACTIVE NOT RECRUITING · Phase 3
-
Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug
COMPLETED · Phase 1
-
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
COMPLETED · Phase 3
-
Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT)
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04353778 · 207 participants · Phase 1
Effects of Vagal Dysfunction on Gastrointestinal and Inflammatory Pathways in HIV
- NCT05875805 · 207 participants · NA
A Telehealth Advance Care Planning Intervention
- NCT06254950 · 207 participants · Phase 2
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
- NCT06904274 · 207 participants · Phase 3
Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI